cases were recruited in our study. RESULTS: The majority of the eligible Medicare beneficiaries responded “not at all likely” to take Part D (62%), and significant propor-
tions also reported “not too likely” to take Part D (21.46%), while few of them reported “somewhat likely” (9.44%) and “very likely” (6.31%). Results of weighted cumulative logit regression indicated that people who had cost barriers in medication use were more likely to not likely or unlikely to take up Medicare Part D (OR=0.92, 95% CI[0.92, 0.94]), p<0.001. Males and older adults were less likely to take up Medicare Part D (OR=0.83, 95% CI[0.74, 0.94] and OR=0.98, 95% CI[0.97, 1.00], p<0.01). CONCLUSIONS: Results of this study indicated experienced CRD was significantly associated with the probability of taking up Part D. CRN could be a motivation of taking up Part D. Thus, characteristics of beneficiaries who reported having CRN, especially those who continued to experience CRN after taking up Part D, need further studies.

MA4

COMPREHENSIVE ASSESSMENT OF PATIENT ADHERENCE TO DRUG THERAPY: AN EXAMPLE UTILIZING REAL WORLD DATA FOR AN ORAL MULTIPLE SCLEROSIS TREATMENT

Irwin DE1, Cappelli KA2, Davis BM3, Wu Y4, Grinspan A4, Gandhik SK1

1Truven Health Analytics, Chapel Hill, NC, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3TEVA Pharmaceuticals, Frazer, PA, USA, 4TEVA Pharmaceuticals, Weston, FL, USA

OBJECTIVES: Medication possession ratio (MPR) and persistence are typically used as measures of patients’ drug use patterns. However, these measures may not capture all aspects related to real world dosing. We aim to explore additional approaches to enhance meaningful interpretation of patients’ drug use patterns using persistence, adherence and average daily dose (ADD) data of dimethyl fuma-
role (DMF) in a real world dataset. METHODS: A retrospective cohort study using the MarketScan Commercial and Medicare Supplemental Database, 2003–2012. Participants were adults with at least one diagnosis of MS. Adherence was determined using persistence, switch to another disease modifying therapy (DMT) or drug discontinuation of ≥ 30 days), adherence (MPR and percent of days covered (PDC)), and estimated ADD. Data were interpreted in the context of the FDA approval; prior analysis in the New England Journal of Medicine: earlier trial (1) reporting dose-related MRI findings indicating non-significant effects on brain lesions for 360 mg/day and 120 mg/day doses. RESULTS: The mean (SD) DMF treatment duration was 96 (66) days (median 83) and 24% of patients became non-persistent. Mean (SD) MPR and PDC were 0.83 (0.26) and 0.75 (0.29), respectively. ADD (SD) was 417 mg/day (221) with 15.3% treated at <360 mg/day and 68.7% treated < 360 mg/day (i.e., 20.3% treated at <360 mg/day and 68.7% treated at less than the labeled dose). CONCLUSIONS: The finding of a large proportion of patients receiving potentially sub-optimal treatment, as determined by ADD on DMF, indicates significant potential clinical consequences for these patients. The approach used in this study could be used in other similar studies to enhance the meaningful interpretation of adherence data. 1. Lancet 2008; 372(9618):1463-72.

MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES

MD1

ECONOMIC EVALUATION OF BST-CASTEL AS AN ADJUNCT TO MICROFRACTURE VERSUS MICROFRACTURE ALONE IN KNEE CARTILAGE SURGERY

Frupper D

Data sources, Blainville, QC, Canada

OBJECTIVES: Knee cartilage damage is a common cause of referral for ortho-
paedic surgery. Treatment aims to reduce pain and symptoms by repairing car-
tilage defects. Knee cartilage repair outcomes, however, treatment might fail after 2-3 years. A Chitosan-Beta-glyceraldehyde bioscaffold used as an adjunct to microfracture and demonstrates improvements in quantity and quality of repaired tissue, potentially reducing the risk of treatment failure. This study aimed to estimate the economic value of bioscaffold versus microfracture alone in knee cartilage repair from the societal perspective, using Germany as the reference market. METHODS: A decision tree with a 20-year time horizon was constructed, in which undesirable clinical events were included following initial surgery. These events consisted of pain management, surgery and total knee replacement. Clinical outcomes were taken from the pivotal clinical trial, supplemented by other literature. Data and assumptions were val-
dated by an internationally recognized Delphi panel. All relevant resource use and costs for procedures and events were considered. RESULTS: In a group of patients with all lesion sizes, the model inferred that bioscaffold yields a positive return on investment at year 4 (with 20-year cumulative cost savings of $6,448). Reducing the incremental risk of treatment failure gap between bioscaffold and microfractu-
ture by 25% to 50% does not alter this conclusion. Cost savings are greatest for patients with larger lesions. Results for patients with small lesions are more mod-
ter. CONCLUSIONS: The Chitosan-Beta glyceraldehyde bioscaffold potentially represents a cost-saving alternative for patients with knee cartilage injury by redu-
ing the risk of clinical events through regeneration of chondral tissue with hyaline characteristic matrix. Additionally, using this clinical event history: ‘insulin only’, ‘insulin with OAD’ or ‘OAD only’ the patient, and society, an effective and economically viable alternative of is importance.

MD2

COVERAGE LIMITS ON BLOOD GLUCOSE TEST STRIP REIMBURSEMENT FOR DIABETICS IN CANADA: UTILIZATION IMPACT FOR DIABETIC PATIENTS IN THE ONTARIO PUBLIC DRUG PROGRAM (OPDP)

Bonnic N1, Goodfellow SM2, Davis BM3, Zhang Y1

1IMS Brogan, Kanata, ON, Canada, 2IMS Brogan, Mississauga, ON, Canada

OBJECTIVES: In August 2013 the Ontario government implemented annual limits on the number of blood glucose test strips (BGTS) it will reimburse for people with diabetes. The change is based on research that shows BGTS have a limited clinical benefit for diabetes patients who do not require insulin. Under the Ontario Public Drug Program (OPDP), the provincial government could pay for up to 200 BGTS per year for patients who require insulin can receive up to 3,000 strips annually. The policy intent was not to change BGTS utilization for insulin patients; however, concerns exist around potential negative impacts on diabetes management. The objective of this analysis is to quantify the impact of this new reimbursement policy in Ontario across diabetes patients based on their diabetes treatment. METHODS: All patients who received BGTS coverage from the OPDP during July 2012 – September 2014 were selected for analysis using the IMS Brogan OPDP Database. Annual BGTS utili-
zation prior to the policy change (July 2012 – June 2013) was then compared to annual BGTS utilization following Ontario’s coverage limit (October 2013 - September 2014). Patients were categorized into one of four cohorts based on their diabetes medica-
tion type: ‘insulin only’, ‘OAD only’, ‘OAD and insulin’ or ‘OAD only non-insulin’. Changes in utilization patterns were assessed for each cohort. RESULTS: 422,525 patients were identified for the pre-period, and 422,154 patients were identified for the post-period. Overall, BGTS utilization declined by 24% following the OPDP policy change. On average, the number of BGTS per patient year decreased for ‘OAD’ and ‘neither’ cohorts by 42% and 54%, respectively. Impact to patients managing diabetes with insulin was minimal: ‘insulin only’ -1% (5%)

MD3

ECONOMIC IMPACT OF CHANGES IN NICU VENTILATION STRATEGIES: A REVIEW AND PERSPECTIVE ASSESSMENT OF THE IMPACT OF NON-INVASIVE HIGH FLOW THERAPY (HT) AS A ROUTINE RESPIRATORY SUPPORT PARADIGM

Patscah JR1, Garnet AM2, McQueen MC3

1Wayne State University, Willowbrook Park, CA, USA, 2Banner Thunderbird Medical Center, Glendale, AZ, USA

OBJECTIVES: High flow therapy (HTF) has been demonstrated to be a safe and effec-
tive noninvasive respiratory support technique for the treatment of pre-term infants in neonatal intensive care units (NICUs). Our objective was to develop a quantita-
tive framework based on available evidence to estimate the economic impact of adoption of a HTF respiratory support strategy compared to standard current to standard care. METHODS: We constructed a model to estimate total cost per NICU patient of each ventilation strategy utilizing different types of ventilatory support modalities – conventional mechanical ventilation (CMV), nasal continuous positive airway pressure (nCPAP) ventilation, and HT – as well as utilization levels of surfactant, chest x-rays, blood gas analyses and total NICU length of stay. Model parameters were derived from a recent study comparing respiratory modality utilization between five US-based neonatal intensive care units (NICUs) adopting a HTF strategy and a larger pool of NICUs in the Vermont-Oxford Network (VON), and from single center experience. We computed the total cost dif-
cerence between the respiratory support strategies based on published cost data. Parameter uncertainty was tested in sensitivity analyses. RESULTS: The base case analysis resulted in total average length of ventilation of 25.48 days for the non-HT strategy (8.92 days nCPAP, 6.10 days HT, 10.47 days CMV) and of 25.06 days (2.88 days nCPAP, 16.86 days HT, 5.32 days CMV) for the HT strategy. HTF was associ-
ated with total projected cost savings of $2,917. Results were sensitive to length of HTF, length of CMV, cost of nCPAP supplies. CONCLUSIONS: Adoption of a HTF strategy appears to be associated with meaningful savings in total NICU episode of care costs, primarily resulting from reductions in the time of conventional mechanical ventilation. Further research is warranted to substantiate these findings.

MD4

ECONOMIC VALUE OF IMPROVED ACCURACY FOR SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 DIABETES

McQueen RP1, Brenot M2, Ott M3, Ria H4, Beamer B5, Campbell JD6

1University of Colorado Anschutz Medical Campus, Denver, CO, USA, 2University of Virginia Health System, Charlottesville, VA, USA, 3Bayer HealthCare, Leverkusen, Germany, 4Bayer HealthCare, Etobicoke, ON, Canada

OBJECTIVES: To simulate and compare clinical and economic outcomes of self-
monitoring of blood glucose (SMBG) devices along accuracy ranges and strip price. METHODS: We programmed a long-term type 1 diabetes natural history and treatment cost-effectiveness model. In phase one, using in Silico modeling validated by the Food and Drug Administration, we associated changes in accu-

racy error rates of SMBG devices to changes in HbA1c (holding glycopregic rates unchanged) and changes in severe hypoglycemia rates requiring an inpatient stay (holding HbA1c levels unchanged). In phase two, using Markov cohort simulation modeling, we estimated lifetime clinical and economic outcomes from the Canadian payer perspective. The primary comparison was a SMBG device with strip price $0.73 Canadian dollars (CAD) with accuracy error rate of 15% versus a SMBG device with strip price $0.60 CAD with accuracy error rate of 5%. Outcomes for the aver-

gage patient, discounted at 3% per annum, were quality-adjusted life years (QALYs), costs, incremental cost-effectiveness ratios (ICERs), and budget impact. RESULTS: Absence of SMBG improvements in both the patient and society, an effective and economically viable alternative of is importance.

A4